Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Expert Opin Pharmacother ; 24(6): 667-674, 2023 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-37013719

RESUMO

INTRODUCTION: Bardet-Biedl Syndrome (BBS) is a rare, multisystemic ciliopathy with an incidence of obesity of 89%. Mutations in genes encoding BBS proteins are linked to reduced leptin sensitivity of hypothalamic POMC neurons and reduced activation of the melanocortin-4 receptor (MC4R) pathway due to deficient α-MSH production by hypothalamic POMC neurons. The MC4R pathway is involved in controlling body weight and energy metabolism, and its disruption is linked to hyperphagia and obesity. Setmelanotide is an MC4R agonist that counteracts deficiencies in the MC4R pathway of individuals with BBS. AREAS COVERED: Data from clinical trials were reviewed along with information available from setmelanotide's approval for treatment of obesity in people ages ≥6y with a clinical diagnosis of BBS. EXPERT OPINION: Setmelanotide is available as a daily injectable that can be used for amelioration of obesity in people with Bardet-Biedl syndrome. Its cost is substantial, which may limit its use, but among those who respond, setmelanotide can reduce body mass dramatically and potentially improve comorbid conditions associated with obesity. Setmelanotide treatment has generally tolerable side effects, primarily injection site reactions and nausea/vomiting that generally improve with continued use; almost all people using setmelanotide experience marked skin darkening due to off-target activation of cutaneous MC1R.


Assuntos
Síndrome de Bardet-Biedl , alfa-MSH , Humanos , Adulto , Criança , alfa-MSH/uso terapêutico , Síndrome de Bardet-Biedl/tratamento farmacológico , Síndrome de Bardet-Biedl/complicações , Síndrome de Bardet-Biedl/genética , Pró-Opiomelanocortina/metabolismo , Pró-Opiomelanocortina/uso terapêutico , Obesidade/complicações , Obesidade/tratamento farmacológico
2.
Diabetes Obes Metab ; 25(6): 1534-1546, 2023 06.
Artigo em Inglês | MEDLINE | ID: mdl-36852745

RESUMO

AIM: To clarify the effects of glucose-dependent insulinotropic polypeptide (GIP) receptor agonists (GIPRAs) on feeding and body weight. MATERIALS AND METHODS: Acute and subchronic effects of subcutaneous GIPFA-085, a long-acting GIPRA, on blood glucose, food intake, body weight, respiratory exchange ratio and plasma leptin levels were measured in diet-induced obese (DIO) mice and/or functional leptin-deficient ob/ob mice. The effects of GIPFA-085 on the hypothalamic arcuate nucleus (ARC) neurons from lean and DIO mice were studied by measuring cytosolic Ca2+ concentration ([Ca2+ ]i ). RESULTS: Single bolus GIPFA-085 (30, 300 nmol/kg) dose-dependently reduced blood glucose in glucose tolerance tests, elevated plasma leptin levels at 0.5-6 hours and inhibited food intake at 2-24 hours after injection in DIO mice. Daily GIPFA-085 (300 nmol/kg) inhibited food intake and increased fat utilization on day 1, and reduced body weight gain on days 3-12 of treatment in DIO, but not ob/ob, mice. GIPFA-085 increased [Ca2+ ]i in the ARC leptin-responsive and proopiomelanocortin (POMC) neurons. GIPFA-085 and leptin cooperated to increase [Ca2+ ]i in ARC neurons and inhibit food intake. CONCLUSIONS: GIPFA-085 acutely inhibits feeding and increases lipid utilization, and sustainedly lowers body weight in DIO mice via mechanisms involving rises in leptin and activation of ARC leptin-responsive and POMC neurons. This study highlights the therapeutic potential of GIPRAs for treating obesity and diabetes.


Assuntos
Núcleo Arqueado do Hipotálamo , Leptina , Camundongos , Animais , Leptina/metabolismo , Pró-Opiomelanocortina/metabolismo , Pró-Opiomelanocortina/farmacologia , Pró-Opiomelanocortina/uso terapêutico , Glicemia , Obesidade/tratamento farmacológico , Obesidade/etiologia , Dieta , Peso Corporal , Receptores Acoplados a Proteínas G , Neurônios/metabolismo , Camundongos Endogâmicos C57BL
3.
BMC Complement Med Ther ; 22(1): 290, 2022 Nov 09.
Artigo em Inglês | MEDLINE | ID: mdl-36352380

RESUMO

BACKGROUND: The restorative effect of classical music was assessed on the cyclophosphamide-induced animal model of premature ovarian failure (POF). METHODS: Mozart's piano classical music (K.448) was used for up to 4 and 8 weeks. Rats were exposed to music 6 h every day using a stereo system with a volume of 65-70 dB. Sera and ovarian tissue samples were collected for the evaluation of FSH, LH, and E2 and histopathological examination. At the same time points, samples were taken from the hypothalamus and hippocampus to monitor the expression of Ntrk2, Crh, and Pomc using real-time PCR. Mating trial was performed to evaluate the fertility status of POF rats. RESULTS: Histopathological examination revealed a significant increase (p < 0.05) in the numbers of morphologically normal follicles at all the developmental stages in POF rats after music therapy compared to the POF group (p < 0.05). Music therapy decreased FSH and LH levels to near-to-normal levels conidied with elevation of E2 (p < 0.05). Ntrk2, Crh, and Pomc expressions were down-regulated in POF rats. Music therapy increasaed the expression of Ntrk2 in the hypothalamus of POF rats (p < 0.05). In contrast, Crh and Pomc failed to reach the detection limit before intervention and four weeks after the intervention however, these genes were expressed eight weeks after music therapy. Fertility status was increased (p < 0.05) in terms of litter size in POF rats after being exposed to music compared to the non-treated POF control group (p < 0.05). CONCLUSION: Results showed that music can exert therapeutic effects on POF rats via the alteration of sex-related hormones.


Assuntos
Música , Insuficiência Ovariana Primária , Humanos , Feminino , Ratos , Animais , Insuficiência Ovariana Primária/terapia , Insuficiência Ovariana Primária/induzido quimicamente , Insuficiência Ovariana Primária/patologia , Pró-Opiomelanocortina/uso terapêutico , Fertilidade , Hormônio Foliculoestimulante
4.
Peptides ; 100: 243-248, 2018 02.
Artigo em Inglês | MEDLINE | ID: mdl-29412826

RESUMO

Identifying peptide hormones with multipotent actions on both weight and glycaemia can have a significant impact on therapeutic options in the treatment of obesity and diabetes. This has been exemplified by recent advances involving pharmacological exploitation of glucagon-like peptide 1 biology. Herein, we summarise evidence supporting the potential candidacy in this light of alpha-melanocyte stimulatory hormone, an endogenous peptide hormone and a breakdown product of the neuropeptide pro-opiomelanocortin. We reference its well described central actions in the control of food intake and moreover highlight new data pointing to an important role for this peptide hormone in the periphery, in relation to glycaemic control.


Assuntos
Diabetes Mellitus/genética , Obesidade/genética , Pró-Opiomelanocortina/genética , alfa-MSH/genética , Peso Corporal/genética , Diabetes Mellitus/metabolismo , Diabetes Mellitus/patologia , Ingestão de Alimentos/genética , Peptídeo 1 Semelhante ao Glucagon/genética , Peptídeo 1 Semelhante ao Glucagon/metabolismo , Humanos , Obesidade/metabolismo , Obesidade/patologia , Pró-Opiomelanocortina/metabolismo , Pró-Opiomelanocortina/uso terapêutico , alfa-MSH/metabolismo
5.
Free Radic Biol Med ; 70: 14-22, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24412703

RESUMO

Hypoxia in the tumor microenvironment triggers differential signaling pathways for tumor survival. In this study, we characterize the involvement of hypoxia and reactive oxygen species (ROS) generation in the antineoplastic mechanism of proopiomelanocortin (POMC) gene delivery in a mouse B16-F10 melanoma model in vivo and in vitro. Histological analysis revealed increased TUNEL-positive cells and enhanced hypoxic activities in melanoma treated with adenovirus encoding POMC (Ad-POMC) but not control vector. Because the apoptotic cells were detected mainly in regions distant from blood vessels, it was hypothesized that POMC therapy might render melanoma cells vulnerable to hypoxic insult. Using a hypoxic chamber or cobalt chloride (CoCl2), we showed that POMC gene delivery elicited apoptosis and caspase-3 activation in cultured B16-F10 cells only under hypoxic conditions. The apoptosis induced by POMC gene delivery was associated with elevated ROS generation in vitro and in vivo. Blocking ROS generation using the antioxidant N-acetyl-l-cysteine abolished the apoptosis and caspase-3 activities induced by POMC gene delivery and hypoxia. We further showed that POMC-derived melanocortins, including α-MSH, ß-MSH, and ACTH, but not γ-MSH, contributed to POMC-induced apoptosis and ROS generation during hypoxia. To elucidate the source of ROS generation, application of the NADPH oxidase inhibitor diphenyleneiodonium attenuated α-MSH-induced apoptosis and ROS generation, implicating the proapoptotic role of NADPH oxidase in POMC action. Of the NADPH oxidase isoforms, only Nox4 was expressed in B16-F10 cells, and Nox4 was also elevated in Ad-POMC-treated melanoma tissues. Silencing Nox4 gene expression with Nox4 siRNA suppressed the stimulatory effect of α-MSH-induced ROS generation and cell apoptosis during hypoxia. In summary, we demonstrate that POMC gene delivery suppressed melanoma growth by inducing apoptosis, which was at least partly dependent on Nox4 upregulation.


Assuntos
Terapia Genética , Melanoma Experimental/genética , NADPH Oxidases/genética , Pró-Opiomelanocortina/genética , Animais , Apoptose/genética , Caspase 3/metabolismo , Técnicas de Transferência de Genes , Melanoma Experimental/tratamento farmacológico , Melanoma Experimental/patologia , Camundongos , NADPH Oxidase 4 , NADPH Oxidases/metabolismo , Pró-Opiomelanocortina/uso terapêutico , Espécies Reativas de Oxigênio/metabolismo , Transdução de Sinais
6.
J Gene Med ; 14(1): 44-53, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22147647

RESUMO

BACKGROUND: Pro-opiomelanocortin (POMC) is the precursor of several neuropeptides, such as corticotropin, melanocyte-stimulating hormone and the endogenous opioid (ß-endorphin). Our previous studies have indicated that POMC gene delivery inhibited the progression and metastasis of B16-F10 melanoma via the α- melanocyte-stimulating hormone/melanortin-1 receptor (MC-1R) pathway. METHODS: In the present study, the therapeutic efficacy of POMC gene therapy was evaluated in mice bearing established Lewis lung carcinoma (LLC) models both in vitro and in vivo. We also investigated the MC-1R-independent mechanism underlying POMC gene therapy. RESULTS: We found that POMC gene delivery significantly inhibited the growth and colony formation in MC-1R-deficient LLC cells. In addition, POMC gene transfer effectively suppressed the growth of established LLC in mice. The inhibitory mechanisms underlying POMC gene delivery were attibuted to be inhibition of proliferation and the induction of apoptosis. Moreover, POMC gene delivery attenuated tumor ß-catenin signaling by reducing protein levels of ß-catenin and its downstream proto-oncogenes, including cyclin D1 and c-myc. Lastly, POMC gene delivery induced a significant suppression of tumor vasculature. CONCLUSIONS: These results support the existence of an MC-1R-independent pathway for POMC gene therapy, which further expands the therapeutic spectrum of POMC therapy for multiple types of cancer.


Assuntos
Carcinoma Pulmonar de Lewis/patologia , Carcinoma Pulmonar de Lewis/terapia , Terapia Genética/métodos , Pró-Opiomelanocortina/genética , Pró-Opiomelanocortina/uso terapêutico , Transdução de Sinais , Animais , Apoptose , Carcinoma Pulmonar de Lewis/irrigação sanguínea , Carcinoma Pulmonar de Lewis/genética , Proliferação de Células , Progressão da Doença , Células Endoteliais/metabolismo , Regulação Neoplásica da Expressão Gênica , Humanos , Camundongos , Camundongos Endogâmicos C57BL , Neovascularização Patológica/terapia , Receptor Tipo 1 de Melanocortina/genética , Receptor Tipo 1 de Melanocortina/metabolismo , beta Catenina/metabolismo
7.
Ann Rheum Dis ; 66 Suppl 3: iii52-5, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17934097

RESUMO

alpha-Melanocyte-stimulating hormone (alpha-MSH) is a tridecapeptide derived from the proopiomelanocortin by post-translational processing. In addition to its effects on melanocytes, alpha-MSH has potent anti-inflammatory effects when administered systemically or locally. The anti-inflammatory effects of alpha-MSH are mediated by direct effects on cells of the immune system as well as indirectly by affecting the function of resident non-immune cells. alpha-MSH affects several pathways implicated in regulation of inflammatory responses such as NF-kappaB activation, expression of adhesion molecules and chemokine receptors, production of pro-inflammatory cytokines and other mediators. Thus alpha-MSH may modulate inflammatory cell proliferation, activity and migration. The anti-inflammatory effects of alpha-MSH have been confirmed by means of animal models of inflammation such as irritant and allergic contact dermatitis, cutaneous vasculitis, asthma, inflammatory bowel disease, rheumatoid arthritis, ocular and brain inflammation. Most of the anti-inflammatory activities of alpha-MSH can be attributed to its C-terminal tripeptide KPV. K(D)PT, a derivative of KPV corresponding to the amino acid 193-195 of IL-1beta, is currently emerging as another tripeptide with potent anti-inflammatory effects. The anti-inflammatory potential together with the favourable physiochemical properties most likely will allow these agents to be developed for the treatment of inflammatory skin, eye and bowel diseases, allergic asthma and arthritis.


Assuntos
Anti-Inflamatórios/uso terapêutico , Imunossupressores/uso terapêutico , Pró-Opiomelanocortina/uso terapêutico , alfa-MSH/análogos & derivados , Animais , Anti-Infecciosos/imunologia , Anti-Infecciosos/uso terapêutico , Anti-Inflamatórios/imunologia , Doenças Ósseas/tratamento farmacológico , Doenças Ósseas/imunologia , Moléculas de Adesão Celular/antagonistas & inibidores , Moléculas de Adesão Celular/imunologia , Citocinas/antagonistas & inibidores , Citocinas/imunologia , Humanos , Imunossupressores/imunologia , Inflamação/tratamento farmacológico , Inflamação/imunologia , Linfócitos/efeitos dos fármacos , Linfócitos/imunologia , Camundongos , Mutação/genética , NF-kappa B/antagonistas & inibidores , NF-kappa B/imunologia , Pró-Opiomelanocortina/imunologia , Receptores de Melanocortina/efeitos dos fármacos , Receptores de Melanocortina/imunologia , alfa-MSH/imunologia , alfa-MSH/uso terapêutico
8.
ScientificWorldJournal ; 6: 1008-23, 2006 Aug 25.
Artigo em Inglês | MEDLINE | ID: mdl-16937007

RESUMO

Cardiovascular disease is a major cause of mortality within the western world affecting 2.7 million British people. This review highlights the beneficial effects of naturally occurring hormones and their peptides, in myocardial ischaemic-injury (MI) models, a disease pathology in which cytokines and neutrophils play a causal role. Here we discuss two distinct classes of endogenous peptides: the steroid inducible annexin 1 and the melanocortin peptides. Annexin 1 and the melanocortins counteract the most important part of the host inflammatory response, namely, the process of leukocyte extravasation, as well as release of proinflammatory mediators. Their biological effects are mediated via the seven transmembrane G-protein-coupled receptors, the fMLP receptor family (or FPR), and the melanocortin receptors, respectively. Pharmacological analysis has demonstrated that the first 24 amino acids of the N-terminus (termed Ac2-26) are the most active region. Both exogenous annexin 1 and its peptides demonstrate cardioprotectiveness and continuing work is required to understand this annexin 1/FPR relationship fully. The melanocortin peptides are derived from a precursor molecule called the POMC protein. These peptides display potent anti-inflammatory effects in human and animal models of disease. In MI, the MC3R has been demonstrated to play an important role in mediating the protective effects of these peptides. The potential anti-inflammatory role for endogenous peptides in cardiac disease is in its infancy. The inhibition of cell migration and release of cytokines and other soluble mediators appears to play an important role in affording protection in ischaemic injury and thus may lead to potential therapeutic targets.


Assuntos
Anexina A1/uso terapêutico , Traumatismo por Reperfusão Miocárdica/tratamento farmacológico , Traumatismo por Reperfusão Miocárdica/prevenção & controle , Fragmentos de Peptídeos/uso terapêutico , Pró-Opiomelanocortina/uso terapêutico , Animais , Anexina A1/química , Anexina A1/metabolismo , Humanos , Traumatismo por Reperfusão Miocárdica/metabolismo , Pró-Opiomelanocortina/química , Pró-Opiomelanocortina/metabolismo , Transdução de Sinais
9.
Biull Eksp Biol Med ; 99(5): 548-9, 1985 May.
Artigo em Russo | MEDLINE | ID: mdl-2860933

RESUMO

A study was made of the effects of some endogenous opioids (beta-endorphin, gamma-endorphin, met-enkephalin, leu-enkephalin and dinorphin) formed in the body from different high-molecular precursors (pro-opiomelanocortin, proenkephalins A and B) on the development in rats of the cysteamine-induced duodenal ulcers. All the peptides under study, gamma-endorphin, in particular, had an anti-ulcerous activity which was mediated by specific opiate receptors. The majority of the opioids was characterized by reduction of the anti-ulcerous effect as the dose was raised. It is assumed that protection of the duodenal mucosa under ulcerogenic exposures is an essential property of endogenous peptides. It is concluded that opioid peptides derived from different precursors are arranged in a complex synergic system responsible for cytoprotection of the duodenum.


Assuntos
Antiulcerosos/uso terapêutico , Úlcera Duodenal/tratamento farmacológico , Encefalinas/uso terapêutico , Animais , Cisteamina/toxicidade , Avaliação Pré-Clínica de Medicamentos , Úlcera Duodenal/induzido quimicamente , Dinorfinas/uso terapêutico , Masculino , Pró-Opiomelanocortina/uso terapêutico , Precursores de Proteínas/uso terapêutico , Ratos , Ratos Endogâmicos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA